Talking to your doctor is an important step in the diagnostic journey, especially if your symptoms are similar to those of heart failure. The earlier the diagnosis, the more of a chance for better clinical outcomes in patients with ATTR-CM.
BridgeBio
Biotechnology Research
Palo Alto, California 40,961 followers
Hope Through Rigorous Science
About us
BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.
- Website
-
http://www.bridgebio.com
External link for BridgeBio
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
- Founded
- 2014
Locations
-
Primary
421 Kipling St
Palo Alto, California, US
Employees at BridgeBio
Updates
-
We’re thrilled to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BBP-812, our investigational AAV9 gene therapy for Canavan disease. We are committed to working closely with the FDA and the Canavan community to develop BBP-812 as fast as possible to address the unmet medical needs of individuals with Canavan disease. Learn more about this exciting development here: https://bit.ly/3Z7IY8m
-
-
In the latest episode of our #OnRarePodcast, Dominic J. Gessler, M.D., Ph.D., UMass Chan Medical School, shares that the genetic disorder is caused by mutations in the ASPA gene, leading to the accumulation of a chemical called N-acetyl-L-aspartic acid (NAA), throughout the body. The accumulation of NAA is thought to damage the white matter in the brain, which causes developmental delays in children. Listen to the full episode here: https://bit.ly/3SLB8xf
-
In the latest episode of our #OnRarePodcast, Dominic J. Gessler, M.D., Ph.D. UMass Chan Medical School, shares that the genetic disorder is caused by mutations in the ASPA gene, leading to the accumulation of a chemical called N-acetyl-L-aspartic acid (NAA), throughout the body. The accumulation of NAA is thought to damage the white matter in the brain, which causes developmental delays in children. Listen to the full episode here: https://bit.ly/3SLB8xf
-
BridgeBio founder & CEO Neil Kumar, Ph.D. is presenting at the Morgan Stanley Global Healthcare Conference today at 10:00 am ET. Join and learn about our work in developing meaningful medicines for people with genetic conditions. Listen to the webcast here: https://bit.ly/3MudAth
-
-
Today, Dr. Mathew Maurer shared insights from our open-label extension of ATTRibute-CM, our Phase 3 trial in patients with transthyretin amyloid cardiomyopathy at the European Society of Cardiology Congress 2024. Learn more about the data: https://bit.ly/4dUcjYg
-
-
At this year’s European Society of Cardiology Congress, Cardiovascular Data Science (CarDS) Lab, led by Dr. Rohan Khera at Yale School of Medicine, will share two oral presentations and two moderated posters about our partnership on multimodal AI that we hope will improve ATTR-CM diagnosis. We welcome clinicians to attend & learn more about innovative approaches to early disease detection. Check out the scientific program to learn more: https://bit.ly/4dGgczS
-
We are excited to announce that new clinical outcomes data from our ATTRibute-CM Phase 3 study of acoramidis will be presented at the European Society of Cardiology (ESC) Congress 2024 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024! These upcoming presentations will showcase the latest advancements and insights into our efforts to address ATTR-CM. Learn more: https://bit.ly/3Xmq10f #Biotech #ClinicalTrials #Cardiology #HeartHealth
-
-
We are hosting a satellite symposium onsite at this year’s European Society of Cardiology with top cardiologists in the space to discuss the important role of transthyretin in ATTR-CM. Learn more about the program: https://bit.ly/3yslD6p
-